Literature DB >> 22628539

Different behaviour of NOX2 activation in patients with paroxysmal/persistent or permanent atrial fibrillation.

Roberto Cangemi1, Andrea Celestini, Camilla Calvieri, Roberto Carnevale, Daniele Pastori, Cristina Nocella, Tommasa Vicario, Pasquale Pignatelli, Francesco Violi.   

Abstract

BACKGROUND: NOX2, the catalytic subunit of NADPH oxidase, is suggested to play a role in favouring the occurrence of atrial fibrillation (AF) after cardiac surgery via formation of reactive oxidant species. However, its role in spontaneous AF is still unclear.
OBJECTIVE: To define the role of NOX2 and isoprostanes, a marker of oxidative stress, in the different settings of AF.
METHODS: The study was performed on 174 patients with AF (82 with paroxysmal/persistent AF and 92 with permanent AF) and 90 controls matched for sex, age and atherosclerotic risk factors. Urinary isoprostanes and serum levels of soluble NOX2-derived peptide (sNOX2-dp) were measured in each patient.
RESULTS: Urinary isoprostanes and sNOX2-dp concentrations were significantly higher in patients with paroxysmal/persistent AF than in those with permanent AF and controls. Compared with controls, patients with permanent AF showed a weak increase in sNOX2-dp and no difference in isoprostanes. Multivariable analyses demonstrated that baseline values of sNOX2-dp and urinary isoprostanes were independently associated with the type of AF (paroxysmal/persistent vs permanent; β=-224, p=0.007 and β=-231, p=0.005, respectively). A significant correlation between sNOX2-dp levels and urinary excretion of isoprostanes was also detected (R=0.707, p<0.001).
CONCLUSIONS: This study provides evidence that NOX2 is upregulated only in patients with paroxysmal/persistent AF and is responsible for overproduction of isoprostanes. This finding warrants further study to see if inhibition of NOX2 may reduce the risk of paroxysmal/persistent AF.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22628539     DOI: 10.1136/heartjnl-2012-301952

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  15 in total

1.  Early decrease of oxidative stress by non-invasive ventilation in patients with acute respiratory failure.

Authors:  Alessia Garramone; Roberto Cangemi; Emanuela Bresciani; Roberto Carnevale; Simona Bartimoccia; Elisa Fante; Marco Corinti; Marco Brunori; Francesco Violi; Giuliano Bertazzoni; Pasquale Pignatelli
Journal:  Intern Emerg Med       Date:  2017-09-15       Impact factor: 3.397

Review 2.  Is there a clinical role for oxidative stress biomarkers in atherosclerotic diseases?

Authors:  Daniele Pastori; Roberto Carnevale; Pasquale Pignatelli
Journal:  Intern Emerg Med       Date:  2013-09-22       Impact factor: 3.397

3.  Serum levels of nicotinamide-adenine dinucleotide phosphate oxidase 4 are associated with non-valvular atrial fibrillation.

Authors:  Tong Liu; Qingmiao Shao; Panagiotis Korantzopoulos; Enzhao Liu; Gang Xu; Guangping Li
Journal:  Biomed Rep       Date:  2015-08-05

Review 4.  Antioxidant therapies for the management of atrial fibrillation.

Authors:  Tong Liu; Panagiotis Korantzopoulos; Guangping Li
Journal:  Cardiovasc Diagn Ther       Date:  2012-12

Review 5.  Mechanisms And Management Of Thrombo-Embolism In Atrial Fibrillation.

Authors:  Francesco Violi; Daniele Pastori; Pasquale Pignatelli
Journal:  J Atr Fibrillation       Date:  2014-10-31

6.  Simvastatin attenuates the oxidative stress, endothelial thrombogenicity and the inducibility of atrial fibrillation in a rat model of ischemic heart failure.

Authors:  Kyoung-Im Cho; Sang-Ho Koo; Tae-Joon Cha; Jung-Ho Heo; Hyun-Su Kim; Gee-Bum Jo; Jae-Woo Lee
Journal:  Int J Mol Sci       Date:  2014-08-22       Impact factor: 5.923

Review 7.  Compromised redox homeostasis, altered nitroso-redox balance, and therapeutic possibilities in atrial fibrillation.

Authors:  Jillian N Simon; Klemen Ziberna; Barbara Casadei
Journal:  Cardiovasc Res       Date:  2016-01-19       Impact factor: 10.787

8.  Discordant Relationships between Systemic Inflammatory Markers and Burden of Oxidative Stress in Patients with Atrial Fibrillation.

Authors:  Jong-Ho Nam; Kyu-Hwan Park; Jung-Hee Lee; Chan-Hee Lee; Jang-Won Son; Ung Kim; Jong-Seon Park; Dong-Gu Shin
Journal:  Korean Circ J       Date:  2017-08-14       Impact factor: 3.243

Review 9.  Targeting inflammation and oxidative stress in atrial fibrillation: role of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibition with statins.

Authors:  Ana Catarina Pinho-Gomes; Svetlana Reilly; Ralf P Brandes; Barbara Casadei
Journal:  Antioxid Redox Signal       Date:  2013-10-19       Impact factor: 8.401

Review 10.  Upstream therapy with statin and recurrence of atrial fibrillation after electrical cardioversion. Review of the literature and meta-analysis.

Authors:  Lorenzo Loffredo; Francesco Angelico; Ludovica Perri; Francesco Violi
Journal:  BMC Cardiovasc Disord       Date:  2012-11-21       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.